Sacutril 200 Tablet

About Sacutril 200 97 mg + 103 mg Tablet

Sacutril 200 is a tablet containing sacubitril 97 mg and valsartan 103 mg. It is a prescription medicine used in heart failure. Always follow your doctor's advice.

There are 25 brands of Sacubitril + Valsartan listed in Bangladesh. 11 of them have a lower unit price than Sacutril 200. The lowest listed price is Arnis 24 mg+26 mg Tablet at ৳ 35.00 per unit.

What is Sacutril 200 97 mg + 103 mg Tablet?

Sacutril 200 is a combination tablet of sacubitril and valsartan, made by Synovia Pharma PLC. It belongs to a group of medicines that act on the heart and blood vessels to help manage heart failure. It is used in adults with long-term heart failure and in children aged one year and older with symptomatic heart failure. It works by increasing certain natural peptides and blocking a substance that raises blood pressure. This medicine is only for use under a doctor's supervision. Do not start, stop, or change it without medical advice.

Uses of Sacutril 200

Sacutril 200 is used to lower the risk of death from heart problems and hospitalization in adults with long-term heart failure and a reduced pumping action of the heart. It is also used to treat symptomatic heart failure in children aged one year and older with a problem in the left side of the heart. Your doctor will decide if it is suitable for you or your child.

How to use Sacutril 200

Take Sacutril 200 exactly as your doctor tells you. The doctor decides the dose and how long you need it. Swallow the tablet with water. You can take it with or without food, but try to take it at the same times each day. Do not crush or chew the tablet unless your doctor says so. If you miss a dose, ask your doctor or pharmacist what to do. Never take extra tablets to make up for a missed one.

Side effects of Sacutril 200

Like all medicines, Sacutril 200 can cause side effects. The most common ones are swelling of the face, lips, or throat (angioedema), low blood pressure, reduced kidney function, high potassium levels in the blood, cough, and dizziness. Some side effects can be serious. Tell your doctor straight away if you have trouble breathing, swelling, or feel very dizzy or faint. Your doctor may need to adjust your treatment.

Safety and precautions

Do not take Sacutril 200 if you are allergic to any of its ingredients, if you have had angioedema after taking an ACE inhibitor or ARB, or if you have hereditary angioedema. Do not take it with an ACE inhibitor or with aliskiren if you have diabetes. Tell your doctor if you have kidney or liver problems, low blood pressure, or high potassium. Talk to your doctor before taking it if you are pregnant, planning pregnancy, or breastfeeding. The doctor will decide if it is safe for you.

Frequently asked questions

How should I store Sacutril 200?

Keep Sacutril 200 in a dry place below 30°C. Protect it from moisture and keep it out of the reach of children. Do not use it after the expiry date printed on the pack.

What is Sacutril 200 used for and what kind of medicine is it?

Sacutril 200 is a tablet for heart failure. It contains sacubitril and valsartan, which work together to help the heart. It is used in adults with long-term heart failure and in children aged one year and older with certain heart problems.

Who should avoid Sacutril 200 or ask a doctor first?

Do not take it if you are allergic to any ingredient, have had angioedema from an ACE inhibitor or ARB, or have hereditary angioedema. Do not use it with an ACE inhibitor or with aliskiren if you have diabetes. Ask your doctor first if you are pregnant, breastfeeding, or have kidney or liver problems.

Can I stop taking Sacutril 200 on my own?

No. Stopping or changing this medicine suddenly can be harmful. Your doctor will decide how long you need it and will tell you if any change is needed. Always talk to your doctor before making any changes.

Indications

This is indicated:
  • To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction.
  • For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.
  • ... Read more
This is indicated:
  • To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction.
  • For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.
  • This is usually administered in conjunction with other heart failure therapies, in place of an angiotensin-converting enzyme inhibitor (ACEi) or other ARB.

Pharmacology

This tablet contains a neprilysin inhibitor, sacubitril, and an angiotensin receptor blocker, valsartan. This tablet inhibits neprilysin (neutral endopeptidase; NEP) via LBQ657, the active metabolite of the prodrug sacubitril, and blocks the angiotensin II type-1 (AT1 ) receptor via valsartan. The cardiovascular and renal effects of this tablet in heart failure patients are attributed to the increased levels of peptides that are degraded by neprilysin, such as natriuretic peptides, by LBQ657, and the simultaneous inhibition of the effects of angiotensin II by valsartan. Valsartan inhibits the effects of angiotensin II by selectively blocking the AT1 receptor, and also inhibits angiotensin II-dependent aldosterone release.

Dosage & Administration

Adult Heart Failure: The recommended starting dose is 49/51 mg orally twice daily. Double the dose after 2 to 4 weeks to the target maintenance dose of 97/103 mg twice daily, as tolerated by the patient.

Reduce the starting dose to 24/26 mg twice daily for:
  • Patients not currently taking an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB) or previously taking a low dose of these agents.
  • Patients with severe renal impairment.
  • Patients with moderate hepatic impairment.
Pediatric Heart Failure: Refer to Table 1 for the recommended dose for pediatric patients aged one year and older. Take the recommended dose orally twice daily. Adjust pediatric patient doses every 2 weeks, as tolerated by the patient.

Recommended Dose Titration-

Pediatric Patients Less than 40 kg:
  • Starting: 1.6 mg/kg
  • Second: 2.3 mg/kg
  • Final: 3.1 mg/kg
Pediatric Patients At least 40 kg, less than 50 kg:
  • Starting: 24/26 mg
  • Second: 49/51 mg
  • Final: 49/51 mg
Pediatric Patients At least 50 kg:
  • Starting: 49/51 mg
  • Second: 72/78 mg
  • Final: 97/103 mg

Interaction

Dual Blockade of the Renin-Angiotensin-Aldosterone System: Should not be used with an ACEi, aliskiren in patients with diabetes, and use with an ARB should be avoided.
Potassium-sparing Diuretics: Serum potassium level may be increased.
NSAIDs: Risk of renal impairment may be increased.
Lithium: Increased risk of lithium toxicity.

Contraindications

This combination is contraindicated:
  • In patients with hypersensitivity to any component
  • In patients with a history of angioedema related to previous ACE inhibitor or ARB therapy 
  • With concomitant use of ACE inhibitors. Do not administer within 36 hours of switching from or to an ACE inhibitor 
  • With concomitant use of aliskiren in patients with diabetes

Side Effects

The most common side effects are Angioedema, Hypotension, Impaired Renal Function, Hyperkalemia, Cough, Dizziness.

Pregnancy & Lactation

Pediatric Use: Safety and effectiveness have not been established in pediatric patients less than 1 year of age.

Geriatric Use: No relevant pharmacokinetic differences have been observed in elderly (>65 years) or very elderly (>75 years) patients compared to the overall population.
 
Hepatic Impairment: No dose adjustment is required when administering this tablet to patients with mild hepatic impairment (Child-Pugh A classification). This tablet is not recommended in patients with severe hepatic impairment, as no studies have been conducted in these patients.

Renal Impairment: No dose adjustment is required in patients with mild (eGFR 60 to 90 ml/min/1.73 m2) to moderate (eGFR 30 to 60 ml/min/1.73 m2) renal impairment. The recommended starting dose in patients with severe renal impairment (eGFR <30 ml/min/1.73 m2) is 24/26 mg twice daily.

Precautions & Warnings

This tablet may cause angioedema and must not be used in patients with a known history of angioedema related to previous ACEi or ARB therapy and in patients with hereditary angioedema.

This tablet lowers blood pressure and may cause symptomatic hypotension. Closely monitor serum creatinine, and down-titrate or interrupt this tablet in patients who develop a clinically significant decrease in renal function. In patients with renal artery stenosis, monitor renal function.

Monitor serum potassium periodically and treat appropriately, especially in patients with risk factors for hyperkalemia such as severe renal impairment, diabetes, hypoaldosteronism, or a high potassium diet. Dosage reduction or interruption of this tablet may be required.

Overdose Effects

Limited data are available with regard to overdosage in human subjects with this tablet. In healthy volunteers, a single dose of this tablet 583 mg sacubitril/617 mg valsartan, and multiple doses of 437 mg sacubitril/463 mg valsartan (14 days) have been studied and were well tolerated. Hypotension is the most likely result of overdosage due to the blood-pressure-lowering effects of this tablet. Symptomatic treatment should be provided. This tablet is unlikely to be removed by hemodialysis because of high protein binding.

Storage Conditions

Keep in a dry place and store below 30°C. Protect from moisture and keep out of the reach of children.

Alternative brands of Sacubitril + Valsartan

Other brands with the same generic name, cheapest first.

See all 25 brands

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.